(Signature page to Indemnification Agreement) TRULIEVE CANNABIS CORP. INDEMNIFICATION AGREEMENT This Indemnification Agreement, dated [_______], 2026, is made between Trulieve Cannabis Corp., a Delaware corporation (the “Company”), and [______________] (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of talented and experienced individuals, such as Indemnitee, to serve as directors and officers of the Company and its subsidiaries and wishes to indemnify its directors and officers to the maximum extent permitted by law; WHEREAS, the Company and Indemnitee recognize that corporate litigation in general has subjected directors and officers to expensive litigation risks; WHEREAS, Section 145 (“Section 145”) of the General Corporation Law of the State of Delaware, as amended (“DGCL”), under which the Company is organized, empowers the Company to indemnify its directors and officers by agreement and to indemnify persons who serve, at the request of the Company, as the directors and officers of other corporations or enterprises, and expressly provides that the indemnification provided by Section 145 is not exclusive; WHEREAS, Section 145(g) of the DGCL allows for the purchase of director and officer liability insurance (“D&O Insurance”) by the Company, which in theory can cover asserted liabilities without regard to whether they are indemnifiable by the Company or not; WHEREAS, individuals considering service or presently serving expect to be extended market terms of indemnification commensurate with their position,

…

LENZ THERAPEUTICS, INC.

OUTSIDE DIRECTOR COMPENSATION POLICY

LENZ Therapeutics, Inc. (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the “Outside Directors”). This Outside Director Compensation Policy (the “Policy”) is intended to formalize the Company’s policy regarding cash compensation and grants of equity awards to its Outside Directors. Unless otherwise defined herein, capitalized terms used in this Policy will have the meaning given such term in the Company’s 2024 Equity Incentive Plan, as amended from time to time (or if such plan no longer is in use at the time of the grant of an equity award, the meaning given such term or any similar term in the equity plan then in place under which such equity award is granted) (such applicable plan, the “Plan”). Each Outside Director will be solely responsible for any tax obligations incurred by such Outside Director as a result of the equity awards and cash and other compensation such Outside Director receives under this Policy.

1.Cash Compensation

a.Annual Cash Retainers for Service as Outside Director. Each Outside Director will be paid a cash retainer of $50,000 per year. There are no per-meeting attendance fees for attending Board meetings or meetings of any committee of the Board.

…

CONSULTING AGREEMENT

Effective April 21, 2026 (“Effective Date”), Dr. Eli Wallace (“Consultant”) and BridgeBio Oncology Therapeutics, Inc. (“Company”) agree as follows:

1.

Services; No Violation of Rights or Obligations. Consultant agrees to undertake and complete the Services (as defined in Exhibit A) in accordance with and on the schedule specified in Attachment A. The only consideration due Consultant regarding the subject matter of this Agreement is set forth on Attachment A. Unless otherwise specifically agreed upon by Company in writing (and notwithstanding any other provision of this Agreement), all activity relating to Services will be performed by and only by Consultant or by employees of Consultant and only those such employees who have been approved in writing in advance by Company.Consultant agrees that it will not (and will not permit others to) violate any agreement with or rights of any third party or, except as expressly authorized by Company in writing hereafter, use or disclose at any time Consultant’s own or any third party’s confidential information or intellectual property in connection with the Services or otherwise for or on behalf of Company.

2.

Ownership Rights; Proprietary Information; Publicity.

a.

…

May 11, 2026

Idan Elmelech

Re: Employment Agreement and Executive Severance Plan Participation Agreement

Dear Idan:

This agreement confirms the terms of your employment as Chief Operating Officer of the Company commencing as of the Effective Date (as defined below). If executed, this Employment Agreement and Executive Severance Plan Participation Agreement (the “Agreement”) shall become effective retroactively as of April 20, 2026 (the “Effective Date”). Except with respect to the Equity Documents, the Restrictive Covenants Agreement (as defined below) and the Severance Plan (each as defined below), this Agreement supersedes in all respects all prior agreements between you and BridgeBio Oncology Therapeutics, Inc. (the “Company”) (or its predecessor(s)) regarding the subject matter herein, including without limitation (i) the Offer Letter, dated April 16, 2024, by and between you and the Company (the “Prior Agreement”) and (ii) any other offer letter, employment agreement or severance agreement.

1.

…

May 11, 2026

Dr. Pedro Beltran

Re: Amended and Restated Employment Agreement and Executive Severance Plan Participation Agreement

Dear Pedro:

This agreement confirms the terms of your employment as Chief Executive Officer of the Company commencing as of the Effective Date (as defined below). If executed, this Amended and Restated Employment Agreement and Executive Severance Plan Participation Agreement (the “Agreement”) shall become effective retroactively as of April 20, 2026 (the “Effective Date”). Except with respect to the Equity Documents, the Restrictive Covenants Agreement (as defined below) and the Severance Plan (each as defined below), this Agreement supersedes in all respects all prior agreements between you and BridgeBio Oncology Therapeutics, Inc. (the “Company”) (or its predecessor(s)) regarding the subject matter herein, including without limitation (i) the Employment Agreement, dated August 11, 2025, by and between you and the Company (the “Prior Agreement”) and (ii) any other offer letter, employment agreement or severance agreement.

1.

…

AMENDMENT NO. 9

TO TRANSITION SERVICES AGREEMENT

This Amendment No. 9 (“Amendment No. 9”) to the Agreement (as defined below) is entered into as of June 23, 2026 (the “Effective Date”) by and among BridgeBio Services Inc., a Delaware corporation (“BBIO”), TheRas, Inc., a Delaware corporation (“BBOT”), BridgeBio Pharma LLC (“BBP LLC”), and BridgeBio Oncology Therapeutics, Inc. (“PubCo”). BBIO, BBOT, BBP LLC and PubCo may be referred to herein by name or individually, as a “Party” and collectively, as the “Parties.” Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Agreement (as defined below) to the extent defined therein.

WHEREAS, BBIO and BBOT entered into that certain Transition Services Agreement, dated April 30, 2024, as amended (the “Agreement”);

WHEREAS, the Parties now wish to further amend the Agreement to update the Service Schedule on Exhibit A thereto;

NOW, THEREFORE, in consideration of the covenants, conditions and undertakings hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

1.

Amendment to Service Schedule. Exhibit A of the Agreement is hereby deleted in its entirety and replaced with the following new Exhibit A attached hereto.

2.

…

IMMUNOME, INC

2024 INDUCEMENT PLAN

EFFECTIVE AS OF: OCTOBER 3, 2024

AMENDED BY THE COMPENSATION COMMITTEE AS OF: MAY 8, 2025 and MAY 12, 2026

1. GENERAL.

(a) Eligible Award Recipients.The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635-1. A person who previously served as an Employee or Director will not be eligible to receive Awards under the Plan, other than following a bona fide period of non-employment. Persons eligible to receive grants of Awards under this Plan are referred to in this Plan as “Eligible Employees.” These Awards must be approved by either a majority of the Company’s “Independent Directors” (as such term is defined in Nasdaq Marketplace Rule 5605(a)(2)) (“Independent Directors”) or the Company’s compensation committee, provided such committee is comprised solely of Independent Directors (the “Independent Compensation Committee”) in order to comply with the exemption from the stockholder approval requirement for “inducement grants” provided under Rule 5635(c)(4) of the Nasdaq Marketplace Rules. Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1 (together with any analogous rules or guidance effective after the date hereof) are referred to in this Plan as the “Inducement Award Rules.”

…

Exhibit 10.7

ENERGY VAULT HOLDINGS, INC.
2022 EQUITY INCENTIVE PLAN
NOTICE OF STOCK OPTION GRANT

You have been granted the following option to purchase shares of the Common Stock of Energy Vault Holdings, Inc. (the “Company”) on the terms and conditions set out below:

Name of Optionee:    [______]

Total Number of Shares:    [______]

Type of Option (U.S. Tax Status):    [Incentive Stock Option][Nonstatutory Stock Option]

Exercise Price per Share:    [______]

Date of Grant:    [______]

Vesting Commencement Date:    [______]

Vesting Schedule:    [To be specified in the individual award agreements]

Expiration Date:    [______]. This option expires earlier if your Service terminates earlier, as described in the Stock Option Agreement, and may terminate earlier in connection with certain corporate transactions as described in Article 9 of the Plan.

You and the Company agree that this option is granted under and governed by the terms and conditions of the Company’s 2022 Equity Incentive Plan, as the same may be amended from time to time (the “Plan”) and the Stock Option Agreement (including, if applicable, the Appendix for Non-U.S. Participants), both of which are attached to, and made a part of, this document. Capitalized terms not otherwise defined herein shall have the meanings assigned to such terms in the Plan.

…

July 13, 2026

Nitin Dahiya

48 Bedford Road

Summit, NJ 07901

n2dahiya@gmail.com

Re:Offer and Terms of Employment

Dear Nitin,

It gives me great pleasure to offer you the position of Chief Financial Officer for Energy Vault Holdings, Inc. (the “Company”). If you accept this offer, the terms and conditions of this offer letter agreement (the “Agreement”), in addition to the attachments enclosed with this Agreement, will apply to your at-will employment with the Company:

1.Start Date and Duties. If you accept this offer, and contingent on the other conditions set forth herein, your first day of employment will be 27 July, 2026. You will report to Robert A. Piconi, Chairman, Co-Founder & Chief Executive Officer. You shall perform duties consistent with your position in a professional and competent manner, and throughout your employment with the Company devote your time to such matters as the Company may reasonably require. You shall use your best efforts to complete all assignments and adhere to the Company’s procedures and policies in effect.

2.Compensation. Your gross annual base salary will be $435,000 USD, subject to standard withholdings and authorized deductions (“Base Salary”), and payable on a bi-weekly basis in accordance with the Company’s normal payroll practices. By virtue of your duties, responsibilities, and compensation, your role is an exempt position, meaning you are not eligible for overtime compensation. Your salary is subject to modification during your employment in accordance with the Company’s practices, policies, or procedures.

…

CALISTOGA RESILIENCY CENTER, LLC

4360 Park Terrace Drive, Suite 100
Westlake Village, CA 91361

					New York, New York August 4, 2025
Re:    Amendment No. 1 to the Note Purchase Agreement
TO EACH OF THE NOTEHOLDERS NAMED ON THE SIGNATURE PAGES HEREOF

Ladies and Gentlemen:

…

DMS_US.374368937.12 124054739.9 LEASE AGREEMENT BETWEEN 184 PROPERTY OWNER, LLC, a New Jersey limited liability company, LANDLORD, -AND- AQUESTIVE THERAPEUTICS, INC., a Delaware corporation, TENANT DATED: , 2026

---

TABLE OF CONTENTS Page -i- ARTICLE 1 DEFINITIONS ................................................................................................. 4 ARTICLE 2 DEMISE, TERM.............................................................................................. 5 ARTICLE 3 BASIC RENT; ADDITIONAL RENT ............................................................ 6 ARTICLE 4 REAL ESTATE TAXES ................................................................................. 7 ARTICLE 5 OPERATING EXPENSES ............................................................................ 10 ARTICLE 6 ELECTRICITY .............................................................................................. 12 ARTICLE 7 MAINTENANCE; ALTERATIONS; REMOVAL OF TRADE FIXTURES .................................................................................................... 13 ARTICLE 8 USE OF PREMISES ...................................................................................... 15 ARTICLE 9 LANDLORD’S SERVICES .......................................................................... 16 ARTICLE 10 COMPLIANCE WITH REQUIREMENTS .................................................. 20 ARTICLE 11 COMPLIANCE WITH ENVIRONMENTAL LAWS .................................. 21 ARTICLE 12 DISCHARGE OF LIENS

…

THE SYMBOL “[****]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. LICENSE AND SUPPLY SECOND AMENDMENT This LICENSE AND SUPPLY SECOND AMENDMENT (“Second Amendment”) is entered into as of 20 April 2026 (the “Second Amendment Effective Date”) by and between Aquestive Therapeutics, Inc., a Delaware corporation having its principal place of business at 30 Technology Drive, Warren, New Jersey 07059 (“Aquestive”), and Atnahs Pharma UK Limited, a company registered in England and Wales having its principal place of business at Sovereign House, Miles Gray Road, Basildon, Essex SS14 3FR (“Pharmanovia”). Aquestive and Pharmanovia are sometimes referred to hereinafter individually as a “Party” and collectively as the “Parties.” RECITALS: A. Aquestive and Pharmanovia entered into a License and Supply Agreement related to the Product in certain territories as specified therein on September 26, 2022, which was subsequently amended by an Amendment Agreement dated 27 March 2023 (together, the “Agreement”). B. Aquestive and Pharmanovia have agreed to enter into this Second Amendment in order to further amend certain terms of the Agreement. C. In consideration of the foregoing and the mutual representations, warranties and covenants contained herein, the Parties, intending to be legally bound hereby, agree as follows: 1. DEFINITIONS Unless otherwise defined in this Second Amendment, capitalized terms used in this Amendment have

…